Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

946 ARTÍCULOS , VIENDO DEL 841 AL 855

Clinical Importance of Amyloid Beta Implication in the Detection and Treatment of Alzheimer's Disease

Pokrzyk J, Kulczyńska-Przybik A, Guzik-Makaruk E, Winkel I, Mroczko B.

Int J Mol Sci. 2025 Feb 24;26(5):1935. doi: 10.3390/ijms26051935.

Successes and failures: the latest advances in the clinical development of amyloid-β-targeting monoclonal antibodies for treating Alzheimer's disease

Panza F, Dibello V, Sardone R, Zupo R, Castellana F, Leccisotti I, Moretti MC, Altamura M, Bellomo A, Daniele A, Solfrizzi V, Resta E, Lozupone M.

Expert Opin Biol Ther. 2025 Mar;25(3):275-283. doi: 10.1080/14712598.2025.2463963. Epub 2025 Feb 7.

Unmasking a Paradox: Roles of the PD-1/PD-L1 Axis in Alzheimer's Disease-Associated Neuroinflammation

Moadab A, Khorramdelazad H, Javar MTA, Nejad MSM, Mirzaie S, Hatami S, Mahdavi N, Ghaffari S, Yazdian FA.

J Neuroimmune Pharmacol. 2025 Apr 26;20(1):46. doi: 10.1007/s11481-025-10206-5.

Exosomes in Alzheimer's disease: From pathogenesis to therapeutics-A comprehensive review of diagnostic and drug delivery applications

Shahlaei M, Afkhami H, Ahmadieh-Yazdi A, Mirmazloumi SH, Sahraei SS, Akbari M, Yang P, Manoochehri H, Tanzadehpanah H, Mahaki H, Sundararaman A, Mohan S, Sheykhhasan M, Al-Musawi S, Dama P.

Biomed Pharmacother. 2025 Nov;192:118548. doi: 10.1016/j.biopha.2025.118548. Epub 2025 Sep 22.

Targeting Transferrin Receptor 1 for Enhancing Drug Delivery Through the Blood-Brain Barrier for Alzheimer's Disease

Shen X, Li H, Zhang B, Li Y, Zhu Z.

Int J Mol Sci. 2025 Oct 8;26(19):9793. doi: 10.3390/ijms26199793.

Precision diagnosis of cognitive impairment due to Alzheimer's disease for therapeutic interventions

Knopman DS.

Alzheimers Dement. 2025 Jan;21(1):e14043. doi: 10.1002/alz.14043. Epub 2024 Dec 24.

A phase 2 randomized, placebo-controlled study on the efficacy and safety of AR1001, a phosphodiesterase-5 inhibitor, in patients with mild-to-moderate Alzheimer's disease

Greeley D, Nash M, Herskowitz B, Kim F, Rock J, Prins N, Kim S, Xi T, Busam JA, Tete B, Choung JJ, Sha SJ.

J Prev Alzheimers Dis. 2025 Nov;12(9):100337. doi: 10.1016/j.tjpad.2025.100337. Epub 2025 Sep 5.

The role of exosomes in diagnosis, pathophysiology, and management of Alzheimer's Disease

Daksh R, Mathew MS, Bosco AM, Sojan C, Tom AA, Bojja SL, Nampoothiri M.

Biochem Biophys Res Commun. 2025 Mar 25;754:151526. doi: 10.1016/j.bbrc.2025.151526. Epub 2025 Feb 21.

From Better Diagnostics to Earlier Treatment: The Rapidly Evolving Alzheimer's Disease Landscape

Bougea A, Debasa-Mouce M, Gulkarov S, Castro-Mosquera M, Reiss AB, Ouro A.

Medicina (Kaunas). 2025 Aug 14;61(8):1462. doi: 10.3390/medicina61081462.

Defining benefit: Clinically and biologically meaningful outcomes in the next-generation Alzheimer's disease clinical care pathway

Elhage A, Cohen S, Cummings J, van der Flier WM, Aisen P, Cho M, Bell J, Hampel H.

Alzheimers Dement. 2025 Feb;21(2):e14425. doi: 10.1002/alz.14425. Epub 2024 Dec 19.

Elevated D-dimer levels after lecanemab infusions: a case report

Zou M, Xu SS, Zhu SG, Yuan CX, Huang JF, Zhu JH, Zhang X, Wang JY.

BMC Geriatr. 2025 Sep 29;25(1):742. doi: 10.1186/s12877-025-06445-z.

Genetically determined Alzheimer's disease research advances: The Down Syndrome & Autosomal Dominant Alzheimer's Disease 2024 Conference

Falgàs N, Maure-Blesa L, Ances B, Flores-Aguilar L, Hartley S, Hassenstab J, Iulita MF, Janicki M, Koenig K, Lao P, Levin J, McDade E, Meijer L, Rafii MS, Snyder HM, Sánchez-Valle R, Fortea J; DSAD‐ADAD conference group; Arriola Infante J, Balasa M, Barroeta I, Barthelemy R N, Bejanin A, Benejam B, Bosch B, Bradshaw A, Carmona-Iragui M, Cohen A, Comas Albertí A, Csincsik L, Cuello AC, Del Hoyo Soriano L, Dijkstra J, Edwards N, Giménez S, Gonzalez-Ortiz F, Gordon B, Gutiérrez Fernández S, Handen B, Jacob C, Johnson E, Johansson C, Lladó A, Lleó A, Morabito S, Morcillo-Nieto AO, Montoliu-Gaya L, Okafor M, Pérez-Millan A, Potier MC, Ringman J, Rodríguez-Baz Í, Rubenstein E, Ryan NS, Strydom A, Vaqué-Alcázar L, Vermunt L, Videla Toro L, Zaman S.

Alzheimers Dement. 2025 Jul;21(7):e70309. doi: 10.1002/alz.70309.

Randomized phase 2a trial assessing a novel septin molecular glue in Alzheimer's disease

Nuytten M, Voets M, Debroux E, Princen K, Pringels L, Fivaz M, Byl E, Ramael S, De Witte K, Boada M, Morató X, Tartari JP, Lafuente A, Macias EF, Matias-Guiu JA, Vijverberg E, Teunissen CE, Anderer P, Staggs V, Hayman V, Corbett A, Ballard C, Harrison JE, Windisch M, Westman AB, Zetterberg H, Dickson S, Mallinckrodt C, Hendrix S, Cummings J, Griffioen G.

Alzheimers Dement. 2025 Sep;21(9):e70537. doi: 10.1002/alz.70537.

Diagnosis of Alzheimer's disease: Recommendations from the French Federation of Memory Clinics

Dumurgier J, Défontaines B, Gallouj K, Garcin B, Garnier-Crussard A, Lagarde J, Pauly JM, Rollin Sillaire A, Rouch-Leroyer I, Sarazin M, Verny M, Wallon D.

Rev Neurol (Paris). 2025 Dec;181(10):1021-1029. doi: 10.1016/j.neurol.2025.09.004. Epub 2025 Sep 30.

Quantum dots in neurotheranostics for the treatment of Alzheimer's disease

Sharma T, Bashir B, Sharma P, Andotra N, Singh SK, Singh TG, Vishwas S.

Ageing Res Rev. 2025 Dec;112:102876. doi: 10.1016/j.arr.2025.102876. Epub 2025 Aug 20.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias